Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers
Current Therapeutic Research, 2014 Background: Efavirenz exhibits multiple interactions with drug-metabolizing enzymes and transporters, and for this reason efavirenz-based HIV therapy is associated with altered pharmacokinetics of coadministered drugs.
Ingrid F. Metzger, PhD +10 more
doaj +1 more source
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. [PDF]
PLoS ONE, 2014 OBJECTIVES: Plasma efavirenz concentrations in HIV-infected patients with tuberculosis (TB) may be affected by cytochrome P450 (CYP) 2B6 single-nucleotide polymorphisms and concurrent rifampicin use.
Kuan-Yeh Lee +9 more
doaj +1 more source
Optimization of diarylazines as anti-HIV agents with dramatically [PDF]
, 2013 Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity.
Anderson, Karen S. +4 more
core +1 more source
Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections [PDF]
Universa Medicina, 2009 The increased percentage of patients with HIV-TB coinfection leads to inevitable interactions between rifampicin and efavirenz. Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection.
Yenny
doaj
Induction of Multiple Drug Transporters by Efavirenz
Journal of Pharmacological Sciences, 2009 Efavirenz, an important component of human immunodeficiency virus 1 (HIV-1) therapy, causes substantial drug interactions as an inducer of cytochromes and the transporter ABCB1. So far its effect on the expression of other transporters is unknown.
Johanna Weiss +5 more
doaj +1 more source
Heliyon, 2021 Efavirenz is inhibitor of non-nucleoside reverse transcriptase enzyme; BCS class II drug. The objective of the present research was to prepare and evaluate nanosuspension of Efavirenz for the treatment of neuro-AIDS.
Smita Kakad, Sanjay Kshirsagar
doaj +1 more source
Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
Universa Medicina, 2016 The increased percentage of patients with HIV-TB coinfection leads to inevitable interactions between rifampicin and efavirenz. Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection.
Yenny Yenny
doaj +1 more source
Asian Pacific Journal of Tropical Medicine, 2020 Objective: To investigate the influence of ABCB1 polymorphisms on the plasma level of efavirenz in Thai adult cases infected with HIV-1. Methods: A single nucleotide polymorphism of ABCB1 3435C>T (rs1045642) in the gene encoding ABCB1 was genotyped using
Sahapat Barusrux +8 more
doaj +1 more source
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration [PDF]
, 2011 Article approval pendingWith expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability and determinants of virologic failure and switching in
Boulle, Andrew +10 more
core +2 more sources
Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa? [PDF]
, 2017 This version is the Accepted Manuscript and is published in final edited form as: AIDS. 2017 January 02; 31(1): 147–157. doi:10.1097/QAD.0000000000001307OBJECTIVE: We assessed the relationship between phasing out stavudine in first-line antiretroviral ...
Bor, Jacob +15 more
core +2 more sources